Literature DB >> 7598816

Immunocytochemical localization of delta opioid receptors in mouse brain.

S B Bausch1, T A Patterson, S M Appleyard, C Chavkin.   

Abstract

An affinity-purified anti-peptide antibody generated against the carboxy-terminal region of the delta opioid receptor was used to localize delta opioid receptors in mouse brain. delta Opioid receptor immunoreactivity was found in axons and nerve terminals in regions of the olfactory bulb, hippocampal formation, cerebral and cerebellar cortex, midbrain and hindbrain. The immunocytochemical distribution correlated well, though not completely with autoradiographic distribution of delta opioid receptors in mouse brain using either [3H][2-D-penicillamine, 5-D-penicillamine]-enkephalin (DPDPE) or [3H]naltrindole. Confocal microscopy of double-labeled tissue provided direct evidence that delta opioid receptors are principally expressed on GABAergic terminals in the hippocampus. These anatomical findings complement extensive physiological studies to provide a more detailed description of endogenous opioid circuitry.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7598816     DOI: 10.1016/0891-0618(94)00044-t

Source DB:  PubMed          Journal:  J Chem Neuroanat        ISSN: 0891-0618            Impact factor:   3.052


  17 in total

1.  Signaling events initiated by kappa opioid receptor activation: quantification and immunocolocalization using phospho-selective KOR, p38 MAPK, and K(IR) 3.1 antibodies.

Authors:  Julia C Lemos; Clarisse A Roth; Charles Chavkin
Journal:  Methods Mol Biol       Date:  2011

2.  Presynaptic versus postsynaptic localization of mu and delta opioid receptors in dorsal and ventral striatopallidal pathways.

Authors:  M F Olive; B Anton; P Micevych; C J Evans; N T Maidment
Journal:  J Neurosci       Date:  1997-10-01       Impact factor: 6.167

3.  Dynorphin up-regulation in the dentate granule cell mossy fiber pathway following chronic inhibition of GluN2B-containing NMDAR is associated with increased CREB (Ser 133) phosphorylation, but is independent of BDNF/TrkB signaling pathways.

Authors:  W Bradley Rittase; Yu Dong; DaRel Barksdale; Zygmunt Galdzicki; Suzanne B Bausch
Journal:  Mol Cell Neurosci       Date:  2014-04-23       Impact factor: 4.314

Review 4.  Olfaction under metabolic influences.

Authors:  Brigitte Palouzier-Paulignan; Marie-Christine Lacroix; Pascaline Aimé; Christine Baly; Monique Caillol; Patrice Congar; A Karyn Julliard; Kristal Tucker; Debra Ann Fadool
Journal:  Chem Senses       Date:  2012-07-25       Impact factor: 3.160

5.  Prolonged morphine treatment selectively increases membrane recruitment of delta-opioid receptors in mouse basal ganglia.

Authors:  Anna Lisa Lucido; Anne Morinville; Louis Gendron; Thomas Stroh; Alain Beaudet
Journal:  J Mol Neurosci       Date:  2005       Impact factor: 3.444

6.  Presynaptic mu and delta opioid receptor modulation of GABAA IPSCs in the rat globus pallidus in vitro.

Authors:  I M Stanford; A J Cooper
Journal:  J Neurosci       Date:  1999-06-15       Impact factor: 6.167

7.  Pre- and postsynaptic actions of opioid and orphan opioid agonists in the rat arcuate nucleus and ventromedial hypothalamus in vitro.

Authors:  P J Emmerson; R J Miller
Journal:  J Physiol       Date:  1999-06-01       Impact factor: 5.182

Review 8.  Neuroprotection against hypoxia/ischemia: δ-opioid receptor-mediated cellular/molecular events.

Authors:  Xiaozhou He; Harleen K Sandhu; Yilin Yang; Fei Hua; Nathalee Belser; Dong H Kim; Ying Xia
Journal:  Cell Mol Life Sci       Date:  2012-09-27       Impact factor: 9.261

9.  mu-Opioid and delta-opioid receptors are expressed in brainstem antinociceptive circuits: studies using immunocytochemistry and retrograde tract-tracing.

Authors:  A E Kalyuzhny; U Arvidsson; W Wu; M W Wessendorf
Journal:  J Neurosci       Date:  1996-10-15       Impact factor: 6.167

Review 10.  Targeting endogenous mu- and delta-opioid receptor systems for the treatment of drug addiction.

Authors:  T S Shippenberg; A LeFevour; V I Chefer
Journal:  CNS Neurol Disord Drug Targets       Date:  2008-11       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.